Business · 19/12/2025Updated: 10/17/2026 · 1 min read
FDA Approves KEYTRUDA QLEX for Rare Pediatric Disease
Summary
The FDA has approved KEYTRUDA QLEX, a treatment for a rare pediatric disease, using a priority review voucher, following a review of its safety and efficacy, which was granted on September 19, 2025.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →